Effects on Atherosclerosis Regression of Ezetimibe or Ezetimibe Plus Simvastatin; Evaluated by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)

• Status: Withdrawn
• Trial end date: 1969-12-31

Summary

18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular inflammation within atherosclerotic plaques. Therefore, in this study the investigators intend to compare the effect of ezetimibe monotherapy or ezetimibe plus statin combination therapy on the atherosclerosis regression using FDG-PET.

• Phase: N/A

Details

• Lead Sponsor: Korea University
• Treatments: Deoxyglucose; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Simvastatin